Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Clinical Interest in BioElectronics’ Products Expands to the Wound Care Market

May 8, 2012

FREDERICK, Md., May 9, 2012 /PRNewswire/ — BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, announces the initiation of two independently run clinical trials on venous stasis ulcers. ActiPatch® and RecoveryRx(TM) use pulsed electromagnetic field therapy to reduce pain and inflammation and promote the healing of injured tissue.

“Clinical research, initiated by facilities independent of the Company, is essential to our future business expansion and revenue growth. Independent research results will assure consumers, health practitioners and governmental health agencies that our products are both highly effective and extremely safe,” said Andrew Whelan, Bioelectronics CEO. “We expect to announce several additional clinical trials in the coming months.”

The two clinical trials are double blind, randomized, and placebo controlled. Both trials are studying the effect of our products on wound healing and the control of wound pain, on venous stasis ulcers, and are currently recruiting patients. One of these important research studies is being conducted by Eric Jaakola DPM, FACFAS, at the Diabetic Foot and Wound Center, Denver, Colorado, and the second study is being undertaken by Dr. Rasmussen, Associate Professor Director of Research, Aarhus University Hospital, Aalborg Hospital, Denmark.

“Venous stasis ulcers are the major cause of chronic wounds, occurring in up to 90% of chronic wound cases,” commented Ian Rawe, Ph.D., the Director of Clinical Research for BioElectronics. “Successful completion of these studies will be of great significance, and will help us attract global medical distributors involved in wound care.”

“Wound care is a multi-billion dollar international market, in which BioElectronics ActiPatch® and RecoveryRx(TM) devices can have a major impact. Additionally, double blind, randomized and placebo controlled trials such as these will help our current distributors to successfully apply for healthcare reimbursement. Reimbursement will significantly expand the use of our RecoveryRx(TM) device for wound care in many of our current distribution territories throughout the world. We anticipate statistically significant results from both clinical trials by the end of the year,” said Dr. Rawe.

About BioElectronics Corporation
BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay(TM) Menstrual Cycle Pain Therapy, and RecoveryRx(TM) for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact: E & E Communications
Paul Knopick
(949) 707-5365

SOURCE BioElectronics Corporation


Source: PR Newswire